Literature DB >> 9559976

Mucosal modulation of immune responses to heat shock proteins in autoimmune arthritis.

D Bonnin1, S Albani.   

Abstract

Induction of oral tolerance to antigens that are targets of self-reactive immune responses is an attractive approach to antigen-specific immune therapy of autoimmune diseases. Oral tolerization has indeed proven to be safe and effective in amelioration of autoimmune diseases in animal models. In humans, results have been somewhat controversial. The emphasis given to clinical outcome rather than to immunomodulation, and the difficulty in identifying appropriate candidate antigens contribute to the controversy. Heat shock proteins are promising targets for immune intervention. Immune reactivity to heat shock proteins has indeed been correlated with autoimmune arthritis in animal models, and abnormal immune responses to heat shock proteins have been described in human arthritis as well. Despite significant recent progress, little is known at a molecular level regarding the mechanisms which are responsible for a switch from autoimmunity to tolerance in humans. This is particularly true with respect to sequential analysis of several molecular and immunologic markers during both the course and treatment of disease. Novel approaches are currently under way to fill the gaps. We will briefly detail here the experience gained to date, and identify some of the avenues which future research will explore.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9559976     DOI: 10.1007/BF02678299

Source DB:  PubMed          Journal:  Biotherapy        ISSN: 0921-299X


  2 in total

Review 1.  Balancing the immune system: Th1 and Th2.

Authors:  W Van Eden; R Van Der Zee; P Van Kooten; S E Berlo; P M Cobelens; A Kavelaars; C J Heijnen; B Prakken; S Roord; S Albani
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

Review 2.  Immunity to heat shock proteins and arthritic disorders.

Authors:  W van Eden
Journal:  Infect Dis Obstet Gynecol       Date:  1999
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.